Targeting vascular (endothelial) dysfunction

British Journal of Pharmacology

Volumn 174, Issue 12, 2017, Pages 1591-1619

  Daiber, Andreas ^a,b   Steven, Sebastian ^a   Weber, Alina ^a   Shuvaev, Vladimir V ^c   Muzykantov, Vladimir R ^c   Laher, Ismail ^d   Li, Huige ^a,b   Lamas, Santiago ^e   Münzel, Thomas ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADIPOSE TISSUE; AGING; AIR POLLUTION; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; DIAGNOSTIC TEST; DIET THERAPY; DISABILITY; DISEASE COURSE; DRUG DELIVERY SYSTEM; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; KINESIOTHERAPY; MEASUREMENT; MENTAL STRESS; NOISE; NONHUMAN; OXIDATIVE STRESS; PHYSIOLOGICAL PROCESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; REGULATORY MECHANISM; REVIEW; TISSUE REPAIR; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASCULITIS; ANIMAL; DRUG EFFECTS; INFLAMMATION; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; OXIDATIVE STRESS;

EID: 84978038789     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13517     Document Type: Review

References (369)

1. Agarwal V, Bell GW, Nam JW, Bartel DP (2015). Predicting effective microRNA target sites in mammalian mRNAs. eLife 4: e05005.
2. Al Mheid I, Held E, Uphoff I, Martin GS, Dunbar S, Bidulescu A et al. (2016). Depressive Symptoms and Subclinical Vascular Disease: The Role of Regular Physical Activity. J Am Coll Cardiol 67: 232–234.
3. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
4. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.
5. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
6. Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729–5743.
7. Anderson RA, Evans LM, Ellis GR, Khan N, Morris K, Jackson SK et al. (2006). Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet Med 23: 258–264.
8. Anderson TJ, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H et al. (2011). Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation 123: 163–169.
9. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D et al. (1995). Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26: 1235–1241.
10. Andreadou I, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, Ferdinandy P (2015). The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol 172: 1587–1606.
11. Andreou I, Sun X, Stone PH, Edelman ER, Feinberg MW (2015). miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med 21: 307–318.
12. Antoniades C, Antonopoulos AS, Bendall JK, Channon KM (2009). Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des 15: 329–342.
13. Antoniades C, Tousoulis D, Tentolouris C, Toutouza M, Marinou K, Goumas G et al. (2003). Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost 89: 990–995.
14. Arnout J, Hoylaerts MF, Lijnen HR (2006). Haemostasis. Handb Exp Pharmacol (176 Pt 2): 1–41.
15. Arpornchayanon W, Canis M, Ihler F, Settevendemie C, Strieth S (2013). TNF-alpha inhibition using etanercept prevents noise-induced hearing loss by improvement of cochlear blood flow in vivo. Int J Audiol 52: 545–552.
16. Aschauer S, Gouya G, Klickovic U, Storka A, Weisshaar S, Vollbracht C et al. (2014). Effect of systemic high dose vitamin C therapy on forearm blood flow reactivity during endotoxemia in healthy human subjects. Vascul Pharmacol 61: 25–29.
17. Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC et al. (2006). The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol 47: 1005–1011.
18. Assmus B, Leistner DM, Schachinger V, Erbs S, Elsasser A, Haberbosch W et al. (2014). Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. Eur Heart J 35: 1275–1283.
19. Atochina EN, Balyasnikova IV, Danilov SM, Granger DN, Fisher AB, Muzykantov VR (1998). Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am J Physiol 275: L806–L817.
20. Bachschmid M, Schildknecht S, Ullrich V (2005). Redox regulation of vascular prostanoid synthesis by the nitric oxide-superoxide system. Biochem Biophys Res Commun 338: 536–542.
21. Bailey JC, Feelisch M, Horowitz JD, Frenneaux MP, Madhani M (2014). Pharmacology and therapeutic role of inorganic nitrite and nitrate in vasodilatation. Pharmacol Ther 144: 303–320.
22. Balci DD, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F et al. (2009). Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 23: 1–6.
23. Balzer J, Rassaf T, Heiss C, Kleinbongard P, Lauer T, Merx M et al. (2008). Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J Am Coll Cardiol 51: 2141–2149.
24. Bar A, Skorka T, Jasinski K, Chlopicki S (2015). MRI-based assessment of endothelial function in mice in vivo. Pharmacol Rep 67: 765–770.
25. Baranska M, Kaczor A, Malek K, Jaworska A, Majzner K, Staniszewska-Slezak E et al. (2015). Raman microscopy as a novel tool to detect endothelial dysfunction. Pharmacol Rep 67: 736–743.
26. Barnard ML, Baker RR, Matalon S (1993). Mitigation of oxidant injury to lung microvasculature by intratracheal instillation of antioxidant enzymes. Am J Physiol 265: L340–L345.
27. Becker L, Prado K, Foppa M, Martinelli N, Aguiar C, Furian T et al. (2012). Endothelial dysfunction assessed by brachial artery ultrasound in severe sepsis and septic shock. J Crit Care 27: e319–e314.
28. Beller CJ, Radovits T, Seres L, Kosse J, Krempien R, Gross ML et al. (2006). Poly(ADP-ribose) polymerase inhibition reverses vascular dysfunction after gamma-irradiation. Int J Radiat Oncol Biol Phys 65: 1528–1535.
29. Bencsik P, Sasi V, Kiss K, Kupai K, Kolossvary M, Maurovich-Horvat P et al. (2015). Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients. Eur J Clin Invest 45: 692–701.
30. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr et al. (2004). Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 109: 613–619.
31. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H (2002). Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 22: 1637–1641.
32. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM et al. (2011). Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121: 2693–2708.
33. Bhatia T, Kapoor A, Kumar J, Sinha A, Ranjan P, Kumar S et al. (2013). Impaired flow-mediated vasodilatation in Asian Indians with erectile dysfunction. Asian J Androl 15: 652–657.
34. Blaes N, Girolami JP (2013). Targeting the ‘Janus face’ of the B2-bradykinin receptor. Expert Opin Ther Targets 17: 1145–1166.
35. Boese JM, Bock M, Schoenberg SO, Schad LR (2000). Estimation of aortic compliance using magnetic resonance pulse wave velocity measurement. Phys Med Biol 45: 1703–1713.
36. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC (1998). Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 32: 1336–1344.
37. Bonetti PO, Barsness GW, Keelan PC, Schnell TI, Pumper GM, Kuvin JT et al. (2003). Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 41: 1761–1768.
38. Boswell-Smith V, Spina D, Page CP (2006). Phosphodiesterase inhibitors. Br J Pharmacol 147 (Suppl 1): S252–S257.
39. Bowler RP, Arcaroli J, Crapo JD, Ross A, Slot JW, Abraham E (2001). Extracellular superoxide dismutase attenuates lung injury after hemorrhage. Am J Respir Crit Care Med 164: 290–294.
40. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V et al. (2003). Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 38: 374–379.
41. Brown NK, Zhou Z, Zhang J, Zeng R, Wu J, Eitzman DT et al. (2014). Perivascular adipose tissue in vascular function and disease: a review of current research and animal models. Arterioscler Thromb Vasc Biol 34: 1621–1630.
42. Bueno M, Wang J, Mora AL, Gladwin MT (2013). Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics. Antioxid Redox Signal 18: 1797–1809.
43. Busse R, Fleming I (2006). Vascular endothelium and blood flow. Handb Exp Pharmacol (176 Pt 2): 43–78.
44. Cahill PA, Redmond EM (2012). Alcohol and cardiovascular disease–modulation of vascular cell function. Nutrients 4: 297–318.
45. Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A et al. (2015). Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med 7: 298ra117.
46. Calver A, Collier J, Vallance P (1992). Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90: 2548–2554.
47. Camici PG, Rimoldi OE, Gaemperli O, Libby P (2012). Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J 33: 1309–1317.
48. Cangemi R, Angelico F, Loffredo L, Del Ben M, Pignatelli P, Martini A et al. (2007). Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radic Biol Med 43: 853–859.
49. Celermajer DS (1997). Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 30: 325–333.
50. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J et al. (1993). Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88: 2149–2155.
51. Chadderdon SM, Belcik JT, Bader L, Kirigiti MA, Peters DM, Kievit P et al. (2014). Proinflammatory endothelial activation detected by molecular imaging in obese nonhuman primates coincides with onset of insulin resistance and progressively increases with duration of insulin resistance. Circulation 129: 471–478.
52. Chakrabarti S, Morton JS, Davidge ST (2014). Mechanisms of estrogen effects on the endothelium: an overview. Can J Cardiol 30: 705–712.
53. Chen AF, Chen DD, Daiber A, Faraci FM, Li H, Rembold CM et al. (2012). Free radical biology of the cardiovascular system. Clin Sci (Lond) 123: 73–91.
54. Chen S, Feng B, George B, Chakrabarti R, Chen M, Chakrabarti S (2010). Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am J Physiol Endocrinol Metab 298: E127–E137.
55. Chen W, Bacanamwo M, Harrison DG (2008). Activation of p300 histone acetyltransferase activity is an early endothelial response to laminar shear stress and is essential for stimulation of endothelial nitric-oxide synthase mRNA transcription. J Biol Chem 283: 16293–16298.
56. Chen Z, Wen L, Martin M, Hsu CY, Fang L, Lin FM et al. (2015). Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of microRNA-92a. Circulation 131: 805–814.
57. Cheng ZJ, Vapaatalo H, Mervaala E (2005). Angiotensin II and vascular inflammation. Med Sci Monit 11: RA194–RA205.
58. Chlopicki S (2015). Perspectives in pharmacology of endothelium: From bench to bedside. Pharmacol Rep 67: vi–ix.
59. Chorny M, Hood E, Levy RJ, Muzykantov VR (2010). Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release 146: 144–151.
60. Closs EI, Ostad MA, Simon A, Warnholtz A, Jabs A, Habermeier A et al. (2012). Impairment of the extrusion transporter for asymmetric dimethyl-l-arginine: A novel mechanism underlying vasospastic angina. Biochem Biophys Res Commun 423: 218–223.
61. Clozel M (2003). Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med 35: 605–613.
62. Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E et al. (2007). A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 167: 1610–1618.
63. Cortese-Krott MM, Kuhnle GG, Dyson A, Fernandez BO, Grman M, DuMond JF et al. (2015). Key bioactive reaction products of the NO/H2S interaction are S/N-hybrid species, polysulfides, and nitroxyl. Proc Natl Acad Sci U S A 112: E4651–E4660.
64. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC et al. (2009). RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20: 742–752.
65. Crabtree MJ, Tatham AL, Al-Wakeel Y, Warrick N, Hale AB, Cai S et al. (2009). Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem 284: 1136–1144.
66. Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, Macallister RJ (2003). Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int 63: 1433–1442.
67. Daiber A, Munzel T (2015). Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress. Antioxid Redox Signal 23: 899–942.
68. Daiber A, Di Lisa F, Oelze M, Kröller-Schön S, Steven S, Schulz E et al. (2017). Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. Br J Pharmacol 174: 1670–1689.
69. Daiber A, Oelze M, Daub S, Steven S, Schuff A, Kroller-Schon S et al. (2014). Vascular Redox Signaling, Redox Switches in Endothelial Nitric Oxide Synthase and Endothelial Dysfunction. In: Laher I (ed). Systems Biology of Free Radicals and Antioxidants, ednSpringer-Verlag: Berlin Heidelberg, pp. 1177–1211.
70. Daniel JM, Penzkofer D, Teske R, Dutzmann J, Koch A, Bielenberg W et al. (2014). Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. Cardiovasc Res 103: 564–572.
71. Dengel DR, Ness KK, Glasser SP, Williamson EB, Baker KS, Gurney JG (2008). Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30: 20–25.
72. Dickinson KM, Clifton PM, Keogh JB (2014). A reduction of 3 g/day from a usual 9 g/day salt diet improves endothelial function and decreases endothelin-1 in a randomised cross_over study in normotensive overweight and obese subjects. Atherosclerosis 233: 32–38.
73. Dimmeler S, Nicotera P (2013). MicroRNAs in age-related diseases. EMBO Mol Med 5: 180–190.
74. Dje N'Guessan P, Riediger F, Vardarova K, Scharf S, Eitel J, Opitz B et al. (2009). Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 29: 380–386.
75. Dogui A, Redheuil A, Lefort M, DeCesare A, Kachenoura N, Herment A et al. (2011). Measurement of aortic arch pulse wave velocity in cardiovascular MR: comparison of transit time estimators and description of a new approach. J Magn Reson Imaging 33: 1321–1329.
76. Dong JY, Zhang YH, Qin LQ (2011). Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 58: 1378–1385.
77. Drake-Holland AJ, Noble MI (2012). Update on the important new drug target in cardiovascular medicine - the vascular glycocalyx. Cardiovasc Hematol Disord Drug Targets 12: 76–81.
78. Drexler H, Hornig B (1999). Endothelial dysfunction in human disease. J Mol Cell Cardiol 31: 51–60.
79. Du YH, Guan YY, Alp NJ, Channon KM, Chen AF (2008). Endothelium-specific GTP cyclohydrolase I overexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension. Circulation 117: 1045–1054.
80. Dunn J, Qiu H, Kim S, Jjingo D, Hoffman R, Kim CW et al. (2014). Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. J Clin Invest 124: 3187–3199.
81. Dziubla TD, Karim A, Muzykantov VR (2005). Polymer nanocarriers protecting active enzyme cargo against proteolysis. J Control Release 102: 427–439.
82. Dziubla TD, Shuvaev VV, Hong NK, Hawkins BJ, Madesh M, Takano H et al. (2008). Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 29: 215–227.
83. Economides PA, Khaodhiar L, Caselli A, Caballero AE, Keenan H, Bursell SE et al. (2005). The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes 54: 204–211.
84. Egert S, Stehle P (2011). Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 14: 121–131.
85. Egert S, Baxheinrich A, Lee-Barkey YH, Tschoepe D, Wahrburg U, Stratmann B (2014). Effects of an energy-restricted diet rich in plant-derived alpha-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits. Br J Nutr 112: 1315–1322.
86. El Assar M, Angulo J, Rodriguez-Manas L (2013). Oxidative stress and vascular inflammation in aging. Free Radic Biol Med 65: 380–401.
87. Ellis GR, Anderson RA, Chirkov YY, Morris-Thurgood J, Jackson SK, Lewis MJ et al. (2001). Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol 37: 564–570.
88. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G et al. (2004). Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292: 1440–1446.
89. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F et al. (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368: 1279–1290.
90. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E et al. (2013). Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166: 199–207 e115.
91. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755–768.
92. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R (2014). Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 66: 1142–1174.
93. Fernandez-Hernando C, Baldan A (2013). MicroRNAs and Cardiovascular Disease. Curr Genet Med Rep 1: 30–38.
94. Fichtlscherer S, Breuer S, Zeiher AM (2004). Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the “vulnerable” patient. Circulation 110: 1926–1932.
95. Forstermann U, Munzel T (2006). Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708–1714.
96. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M et al. (2008). Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118: 818–827.
97. Frantz S, Adamek A, Fraccarollo D, Tillmanns J, Widder JD, Dienesch C et al. (2009). The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol 104: 773–779.
98. Freeman BA, Turrens JF, Mirza Z, Crapo JD, Young SL (1985). Modulation of oxidant lung injury by using liposome-entrapped superoxide dismutase and catalase. Fed Proc 44: 2591–2595.
99. Frolow M, Drozdz A, Kowalewska A, Nizankowski R, Chlopicki S (2015). Comprehensive assessment of vascular health in patients; towards endothelium-guided therapy. Pharmacol Rep 67: 786–792.
100. Fujii H, Berliner LJ (2004). Detection of bioradicals by in vivo L-band electron spin resonance spectrometry. NMR Biomed 17: 311–318.
101. Furchgott RF, Zawadzki JV (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373–376.
102. Galie N, Manes A, Branzi A (2001). Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 22: 529–537, x.
103. Garcia MM, Lima PR, Correia LC (2012). Prognostic value of endothelial function in patients with atherosclerosis: systematic review. Arq Bras Cardiol 99: 857–865.
104. Ghiadoni L, Cupisti A, Huang Y, Mattei P, Cardinal H, Favilla S et al. (2004). Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 17: 512–519.
105. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC et al. (2013a). Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369: 330–340.
106. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH et al. (2013b). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369: 319–329.
107. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA (2002). Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105: 1567–1572.
108. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO et al. (2003). Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41: 1769–1775.
109. Gonzalez MA, Selwyn AP (2003). Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 115 (Suppl 8A): 99S–106S.
110. Goodyear LJ (2008). The exercise pill–too good to be true? N Engl J Med 359: 1842–1844.
111. Gori T, Parker JD (2004). Long-term therapy with organic nitrates: the pros and cons of nitric oxide replacement therapy. J Am Coll Cardiol 44: 632–634.
112. Gori T, Munzel T (2011). Oxidative stress and endothelial dysfunction: therapeutic implications. Ann Med 43: 259–272.
113. Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S et al. (2001). Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 104: 1119–1123.
114. Gori T, Dragoni S, Lisi M, Di Stolfo G, Sonnati S, Fineschi M et al. (2008). Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol 51: 1953–1958.
115. Gori T, Muxel S, Damaske A, Radmacher MC, Fasola F, Schaefer S et al. (2012). Endothelial function assessment: flow-mediated dilation and constriction provide different and complementary information on the presence of coronary artery disease. Eur Heart J 33: 363–371.
116. Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW et al. (2015). Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circ Res 117: 645–654.
117. Groot HJ, Trinity JD, Layec G, Rossman MJ, Ives SJ, Morgan DE et al. (2015). The role of nitric oxide in passive leg movement-induced vasodilatation with age: insight from alterations in femoral perfusion pressure. J Physiol 593: 3917–3928.
118. Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM et al. (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373: 2103–2116.
119. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH (2009). Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 61: 1396–1402.
120. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA et al. (2002). Prognostic value of coronary vascular endothelial dysfunction. Circulation 106: 653–658.
121. Han J, Shuvaev VV, Muzykantov VR (2012). Targeted interception of signaling reactive oxygen species in the vascular endothelium. Ther Deliv 3: 263–276.
122. Hansel S, Lassig G, Pistrosch F, Passauer J (2003). Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170: 177–180.
123. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H (2003). Role of oxidative stress in atherosclerosis. Am J Cardiol 91: 7A–11A.
124. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR et al. (2011). Inflammation, immunity, and hypertension. Hypertension 57: 132–140.
125. Heiss C, Kleinbongard P, Dejam A, Perre S, Schroeter H, Sies H et al. (2005). Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol 46: 1276–1283.
126. Heitzer T, Just H, Munzel T (1996a). Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 94: 6–9.
127. Heitzer T, Krohn K, Albers S, Meinertz T (2000a). Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43: 1435–1438.
128. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T (2001). Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104: 2673–2678.
129. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T (2005). Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 25: 1174–1179.
130. Heitzer T, Ylä-Herttuala S, Luoma J, Kurz S, Munzel T, Just H et al. (1996b). Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 93: 1346–1353.
131. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S et al. (2000b). Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 86: E36–E41.
132. Henry RM, Ferreira I, Kostense PJ, Dekker JM, Nijpels G, Heine RJ et al. (2004). Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis 174: 49–56.
133. Herrera MD, Mingorance C, Rodriguez-Rodriguez R, Alvarez de Sotomayor M (2010). Endothelial dysfunction and aging: an update. Ageing Res Rev 9: 142–152.
134. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al. (2003). Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593–600.
135. Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A et al. (2003). Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 42: 1826–1834.
136. Hood E, Simone E, Wattamwar P, Dziubla T, Muzykantov V (2011). Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond) 6: 1257–1272.
137. Hood ED, Chorny M, Greineder CF, A SA, Levy RJ, Muzykantov VR (2014). Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials 35: 3708–3715.
138. Hood ED, Greineder CF, Dodia C, Han J, Mesaros C, Shuvaev VV et al. (2012). Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. J Control Release 163: 161–169.
139. Howard MD, Greineder CF, Hood ED, Muzykantov VR (2014a). Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J Control Release 177: 34–41.
140. Howard MD, Hood ED, Greineder CF, Alferiev IS, Chorny M, Muzykantov V (2014b). Targeting to endothelial cells augments the protective effect of novel dual bioactive antioxidant/anti-inflammatory nanoparticles. Mol Pharm 11: 2262–2270.
141. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X et al. (2013). Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 123: 3815–3828.
142. Hughes WE, Kruse NT (2016). A ‘passive’ movement into the future of assessing endothelial dysfunction? J Physiol 594: 1525–1526.
143. Hyndman KA, Ho DH, Sega MF, Pollock JS (2014). Histone deacetylase 1 reduces NO production in endothelial cells via lysine deacetylation of NO synthase 3. Am J Physiol Heart Circ Physiol 307: H803–H809.
144. Jablonski KL, Seals DR, Eskurza I, Monahan KD, Donato AJ (2007). High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men. J Appl Physiol 103: 1715–1721.
145. Jankovic A, Korac A, Buzadzic B, Otasevic V, Stancic A, Daiber A et al. (2015). Redox implications in adipose tissue (dys)function-A new look at old acquaintances. Redox Biol 6: 19–32.
146. Jankovic A, Korac A, Buzadzic B, Stancic A, Otasevic V, Ferdinandy P et al. (2017). Targeting the NO/superoxide ratio in adipose tissue: relevance to obesity and diabetes management. Br J Pharmacol 174: 1570–1590.
147. Jiang YZ, Jimenez JM, Ou K, McCormick ME, Zhang LD, Davies PF (2014). Hemodynamic disturbed flow induces differential DNA methylation of endothelial Kruppel-Like Factor 4 promoter in vitro and in vivo. Circ Res 115: 32–43.
148. Johnson BD, Mather KJ, Wallace JP (2011). Mechanotransduction of shear in the endothelium: basic studies and clinical implications. Vasc Med 16: 365–377.
149. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R et al. (2000). Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol 32: 1429–1437.
150. Kahler J, Ewert A, Weckmuller J, Stobbe S, Mittmann C, Koster R et al. (2001). Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol 38: 49–57.
151. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ (2004). Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43: 179–184.
152. Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A et al. (2015). Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 38: 119–125.
153. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A et al. (2014). Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 35: 578–589.
154. Karbach S, Wenzel P, Waisman A, Munzel T, Daiber A (2014a). eNOS uncoupling in cardiovascular diseases–the role of oxidative stress and inflammation. Curr Pharm Des 20: 3579–3594.
155. Karbach S, Croxford AL, Oelze M, Schuler R, Minwegen D, Wegner J et al. (2014b). Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34: 2658–2668.
156. Katsume A, Okigaki M, Matsui A, Che J, Adachi Y, Kishita E et al. (2011). Early inflammatory reactions in atherosclerosis are induced by proline-rich tyrosine kinase/reactive oxygen species-mediated release of tumor necrosis factor-alpha and subsequent activation of the p21Cip1/Ets-1/p300 system. Arterioscler Thromb Vasc Biol 31: 1084–1092.
157. Katz DL, Meller S (2014). Can we say what diet is best for health? Annu Rev Public Health 35: 83–103.
158. Khaw KT, Bingham S, Welch A, Luben R, Wareham N, Oakes S et al. (2001). Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 357: 657–663.
159. Kim GH, Ryan JJ, Archer SL (2013). The role of redox signaling in epigenetics and cardiovascular disease. Antioxid Redox Signal 18: 1920–1936.
160. Kleschyov AL, Sen VD (2013). Heparin-polynitroxide derivatives: a platform for new diagnostic and therapeutic agents in cardiovascular disease? Future Med Chem 5: 385–388.
161. Kleschyov AL, Sen V, Golubev V, Munnemann K, Hinderberger D, Lackner KJ et al. (2012). Heparin-polynitroxides: synthesis and preliminary evaluation as cardiovascular EPR/MR imaging probes and extracellular space-targeted antioxidants. Eur J Med Chem 58: 265–271.
162. Klonizakis M, Alkhatib A, Middleton G (2014). Long-term effects of an exercise and Mediterranean diet intervention in the vascular function of an older, healthy population. Microvasc Res 95: 103–107.
163. Knorr M, Munzel T, Wenzel P (2014). Interplay of NK cells and monocytes in vascular inflammation and myocardial infarction. Front Physiol 5: 295.
164. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403.
165. Kontush A (2014). HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res 103: 341–349.
166. Korkmaz S, Radovits T, Barnucz E, Neugebauer P, Arif R, Hirschberg K et al. (2009a). Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta. Eur J Pharmacol 615: 155–162.
167. Korkmaz S, Radovits T, Barnucz E, Hirschberg K, Neugebauer P, Loganathan S et al. (2009b). Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation 120: 677–686.
168. Korkmaz S, Loganathan S, Mikles B, Radovits T, Barnucz E, Hirschberg K et al. (2013). Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta. J Cardiovasc Pharmacol Ther 18: 70–77.
169. Kovacs I, Csaszar A, Toth J, Siller G, Farkas A, Tarjan J et al. (2008). Correlation between flow-mediated dilation and erectile dysfunction. J Cardiovasc Pharmacol 51: 148–153.
170. Kozower BD, Christofidou-Solomidou M, Sweitzer TD, Muro S, Buerk DG, Solomides CC et al. (2003). Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol 21: 392–398.
171. Krishnan RM, Adar SD, Szpiro AA, Jorgensen NW, Van Hee VC, Barr RG et al. (2012). Vascular responses to long- and short-term exposure to fine particulate matter: MESA Air (Multi-Ethnic Study of Atherosclerosis and Air Pollution). J Am Coll Cardiol 60: 2158–2166.
172. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE et al. (2005). Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481–484.
173. Kumar A, Kumar S, Vikram A, Hoffman TA, Naqvi A, Lewarchik CM et al. (2013). Histone and DNA methylation-mediated epigenetic downregulation of endothelial Kruppel-like factor 2 by low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 33: 1936–1942.
174. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109–1122.
175. Landberg R, Naidoo N, van Dam RM (2012). Diet and endothelial function: from individual components to dietary patterns. Curr Opin Lipidol 23: 147–155.
176. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J et al. (2009). Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119: 2781–2788.
177. Lau D, Baldus S (2006). Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 111: 16–26.
178. Laufs U, Wassmann S, Czech T, Munzel T, Eisenhauer M, Bohm M et al. (2005). Physical Inactivity Increases Oxidative Stress, Endothelial Dysfunction, and Atherosclerosis. Arterioscler Thromb Vasc Biol 25: 809–814.
179. Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR Jr (2004). Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 80: 1194–1200.
180. Lehmann ED, Parker JR, Hopkins KD, Taylor MG, Gosling RG (1993). Validation and reproducibility of pressure-corrected aortic distensibility measurements using pulse-wave-velocity Doppler ultrasound. J Biomed Eng 15: 221–228.
181. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J et al. (2011). Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 18: 775–789.
182. Leskinen T, Usenius JP, Alen M, Kainulainen H, Kaprio J, Kujala UM (2011). Leisure-time physical activity and artery lumen diameters: a monozygotic co-twin control study. Scand J Med Sci Sports 21: e208–e214.
183. Ley SH, Hamdy O, Mohan V, Hu FB (2014). Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet 383: 1999–2007.
184. Li S, Laher I (2015). Exercise Pills: At the Starting Line. Trends Pharmacol Sci 36: 906–917.
185. Libby P (2002). Inflammation in atherosclerosis. Nature 420: 868–874.
186. Libby P, Aikawa M, Jain MK (2006). Vascular endothelium and atherosclerosis. Handb Exp Pharmacol : 285–306.
187. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2224–2260.
188. Lippi G, Montagnana M, Favaloro EJ, Franchini M (2009). Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost 35: 325–336.
189. Loyer X, Potteaux S, Vion AC, Guerin CL, Boulkroun S, Rautou PE et al. (2014). Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 114: 434–443.
190. Lucas DL, Brown RA, Wassef M, Giles TD (2005). Alcohol and the cardiovascular system: research challenges and opportunities. J Am Coll Cardiol 45: 1916–1924.
191. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW et al. (1986). Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046–1051.
192. Magenta A, Cencioni C, Fasanaro P, Zaccagnini G, Greco S, Sarra-Ferraris G et al. (2011). miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 18: 1628–1639.
193. Mangoni AA, Sherwood RA, Swift CG, Jackson SH (2002). Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med 252: 497–503.
194. Mangoni AA, Sherwood RA, Asonganyi B, Swift CG, Thomas S, Jackson SH (2005). Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 18: 220–226.
195. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y et al. (2013). Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study. Heart 99: 1837–1842.
196. Marvar PJ, Harrison DG (2012a). Stress-dependent hypertension and the role of T lymphocytes. Exp Physiol 97: 1161–1167.
197. Marvar PJ, Vinh A, Thabet S, Lob HE, Geem D, Ressler KJ et al. (2012b). T lymphocytes and vascular inflammation contribute to stress-dependent hypertension. Biol Psychiatry 71: 774–782.
198. Matsuzawa Y, Sugiyama S, Sumida H, Sugamura K, Nozaki T, Ohba K et al. (2013). Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc 2: e000426.
199. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB et al. (2007). SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 104: 14855–14860.
200. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010). Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31: 1000–1006.
201. Menghini R, Stohr R, Federici M (2014). MicroRNAs in vascular aging and atherosclerosis. Ageing Res Rev 17: 68–78.
202. Merino J, Ferre R, Girona J, Aguas D, Cabre A, Plana N et al. (2015). Physical activity below the minimum international recommendations improves oxidative stress, ADMA levels, resting heart rate and small artery endothelial function. Clin Investig Arterioscler 27: 9–16.
203. Meuwese MC, Mooij HL, Nieuwdorp M, van Lith B, Marck R, Vink H et al. (2009). Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J Lipid Res 50: 148–153.
204. Mikhed Y, Daiber A, Steven S (2015a). Mitochondrial Oxidative Stress, Mitochondrial DNA Damage and Their Role in Age-Related Vascular Dysfunction. Int J Mol Sci 16: 15918–15953.
205. Mikhed Y, Gorlach A, Knaus UG, Daiber A (2015b). Redox regulation of genome stability by effects on gene expression, epigenetic pathways and DNA damage/repair. Redox Biol 5: 275–289.
206. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL (1998). Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298–1305.
207. Mitchell GF (2015). Arterial stiffness: insights from Framingham and Iceland. Curr Opin Nephrol Hypertens 24: 1–7.
208. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G et al. (2008). Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117: 2626–2636.
209. Mombouli JV, Vanhoutte PM (1999). Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 31: 61–74.
210. Moncada S, Higgs EA (2006). Nitric oxide and the vascular endothelium. Handb Exp Pharmacol (176 Pt 1): 213–254.
211. Montero D, Padilla J, Diaz-Canestro C, Muris DM, Pyke KE, Obert P et al. (2014). Flow-mediated dilation in athletes: influence of aging. Med Sci Sports Exerc 46: 2148–2158.
212. Moreira DM, Lueneberg ME, da Silva RL, Fattah T, Mascia Gottschall CA (2013). Rationale and design of the TETHYS trial: the effects of methotrexate therapy on myocardial infarction with ST-segment elevation. Cardiology 126: 167–170.
213. Munzel T (2008). Endothelial dysfunction: pathophysiology, diagnosis and prognosis. Dtsch Med Wochenschr 133: 2465–2470.
214. Munzel T, Daiber A, Gori T (2011). Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123: 2132–2144.
215. Munzel T, Daiber A, Gori T (2013). More answers to the still unresolved question of nitrate tolerance. Eur Heart J 34: 2666–2673.
216. Munzel T, Hink U, Heitzer T, Meinertz T (1999). Role for NADPH/NADH oxidase in the modulation of vascular tone. Ann N Y Acad Sci 874: 386–400.
217. Munzel T, Gori T, Babisch W, Basner M (2014a). Cardiovascular effects of environmental noise exposure. Eur Heart J 35: 829–836.
218. Munzel T, Sinning C, Post F, Warnholtz A, Schulz E (2008). Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 40: 180–196.
219. Munzel T, Meinertz T, Tebbe U, Schneider HT, Stalleicken D, Wargenau M et al. (2014b). Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial. Eur Heart J 35: 895–903.
220. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spano F, Puppo F (2012). Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224: 309–317.
221. Muro S, Cui X, Gajewski C, Murciano JC, Muzykantov VR, Koval M (2003). Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol 285: C1339–C1347.
222. Muro S, Mateescu M, Gajewski C, Robinson M, Muzykantov VR, Koval M (2006). Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol 290: L809–L817.
223. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C et al. (2012). GBD 2010: design, definitions, and metrics. Lancet 380: 2063–2066.
224. Muzykantov VR, Sakharov DV, Domogatsky SP, Goncharov NV, Danilov SM (1987). Directed targeting of immunoerythrocytes provides local protection of endothelial cells from damage by hydrogen peroxide. Am J Pathol 128: 276–285.
225. Muzykantov VR, Atochina EN, Ischiropoulos H, Danilov SM, Fisher AB (1996). Immunotargeting of antioxidant enzyme to the pulmonary endothelium. Proc Natl Acad Sci U S A 93: 5213–5218.
226. Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW et al. (2007). Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167: 1262–1270.
227. Nelson MR, Stepanek J, Cevette M, Covalciuc M, Hurst RT, Tajik AJ (2010). Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc 85: 460–472.
228. Neunteufl T, Priglinger U, Heher S, Zehetgruber M, Soregi G, Lehr S et al. (2000). Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J Am Coll Cardiol 35: 277–283.
229. Nieuwdorp M, Meuwese MC, Mooij HL, Ince C, Broekhuizen LN, Kastelein JJ et al. (2008). Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. J Appl Physiol 104: 845–852.
230. Nowak K, Hanusch C, Nicksch K, Metzger RP, Beck G, Gebhard MM et al. (2010). Pre-ischaemic conditioning of the pulmonary endothelium by immunotargeting of catalase via angiotensin-converting-enzyme antibodies. Eur J Cardiothorac Surg 37: 859–863.
231. Okui H, Hamasaki S, Ishida S, Kataoka T, Orihara K, Fukudome T et al. (2008). Adiponectin is a better predictor of endothelial function of the coronary artery than HOMA-R, body mass index, immunoreactive insulin, or triglycerides. Int J Cardiol 126: 53–61.
232. Pandey D, Sikka G, Bergman Y, Kim JH, Ryoo S, Romer L et al. (2014). Transcriptional regulation of endothelial arginase 2 by histone deacetylase 2. Arterioscler Thromb Vasc Biol 34: 1556–1566.
233. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE (1990). Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22–27.
234. Parthasarathy S, Khan-Merchant N, Penumetcha M, Khan BV, Santanam N (2001). Did the antioxidant trials fail to validate the oxidation hypothesis? Curr Atheroscler Rep 3: 392–398.
235. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko YA et al. (2016). Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease. Circulation 133: 361–369.
236. Pauriah M, Khan F, Lim TK, Elder DH, Godfrey V, Kennedy G et al. (2012). B-type natriuretic peptide is an independent predictor of endothelial function in man. Clin Sci (Lond) 123: 307–312.
237. Pena AS, Wiltshire E, Gent R, Hirte C, Couper J (2004). Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr 144: 500–504.
238. Perng JK, Lee S, Kundu K, Caskey CF, Knight SF, Satir S et al. (2012). Ultrasound imaging of oxidative stress in vivo with chemically-generated gas microbubbles. Ann Biomed Eng 40: 2059–2068.
239. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A et al. (2001). Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104: 191–196.
240. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al. (2010). EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69: 325–331.
241. Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S et al. (2007). Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 20: 392–397.
242. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA (2002). Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 106: 184–190.
243. Preissler G, Loehe F, Huff IV, Ebersberger U, Shuvaev VV, Bittmann I et al. (2011). Targeted Endothelial Delivery of Nanosized Catalase Immunoconjugates Protects Lung Grafts Donated After Cardiac Death. Transplantation 92: 380–387.
244. Pries AR, Kuebler WM (2006). Normal endothelium. Handb Exp Pharmacol (176 Pt 1): 1–40.
245. Raaschou-Nielsen O, Andersen ZJ, Jensen SS, Ketzel M, Sorensen M, Hansen J et al. (2012). Traffic air pollution and mortality from cardiovascular disease and all causes: a Danish cohort study. Environ Health 11: 60.
246. Radermacher KA, Beghein N, Boutry S, Laurent S, Vander Elst L, Muller RN et al. (2009). In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: a multimodal approach using MR imaging and EPR spectroscopy. Invest Radiol 44: 398–404.
247. Radovits T, Lin LN, Zotkina J, Gero D, Szabo C, Karck M et al. (2007a). Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur J Pharmacol 564: 158–166.
248. Radovits T, Seres L, Gero D, Berger I, Szabo C, Karck M et al. (2007b). Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction. Exp Gerontol 42: 676–685.
249. Radovits T, Korkmaz S, Miesel-Groschel C, Seidel B, Stasch JP, Merkely B et al. (2011). Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg 39: 248–255.
250. Radovits T, Arif R, Bomicke T, Korkmaz S, Barnucz E, Karck M et al. (2013). Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil. Eur J Pharmacol 710: 110–119.
251. Radovits T, Zotkina J, Lin LN, Bomicke T, Arif R, Gero D et al. (2007c). Poly(ADP-Ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite. Exp Biol Med 232: 1204–1212.
252. Radovits T, Bomicke T, Kokeny G, Arif R, Loganathan S, Kecsan K et al. (2009). The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol 156: 909–919.
253. Rammos C, Hendgen-Cotta UB, Sobierajski J, Bernard A, Kelm M, Rassaf T (2014). Dietary nitrate reverses vascular dysfunction in older adults with moderately increased cardiovascular risk. J Am Coll Cardiol 63: 1584–1585.
254. Ramsey M, Goodfellow J, Bellamy M, Lewis M, Henderson A (1996). Non-invasive detection of endothelial dysfunction. Lancet 348: 128–129.
255. Rao X, Zhong J, Zhang S, Zhang Y, Yu Q, Yang P et al. (2011). Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury. Circulation 123: 2964–2974.
256. Ras RT, Streppel MT, Draijer R, Zock PL (2013). Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol 168: 344–351.
257. Rassaf T, Ferdinandy P, Schulz R (2014). Nitrite in organ protection. Br J Pharmacol 171: 1–11.
258. Rassaf T, Rammos C, Hendgen-Cotta UB, Heiss C, Kleophas W, Dellanna F et al. (2016). Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis: A Double-Blind, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol 11: 108–118.
259. Reference Values for Arterial Stiffness' Collaboration (2010). Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 31: 2338–2350.
260. Regensteiner JG, Popylisen S, Bauer TA, Lindenfeld J, Gill E, Smith S et al. (2003). Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med 8: 169–175.
261. Ridker PM, Thuren T, Zalewski A, Libby P (2011). Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162: 597–605.
262. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. (2005). C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28.
263. Risbano MG, Gladwin MT (2013). Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. Handb Exp Pharmacol 218: 315–349.
264. Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD et al. (2009). Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther 124: 279–300.
265. Riwanto M, Landmesser U (2013). High-density lipoproteins and Endothelial Functions: Mechanistic Insights and Alterations in Cardiovascular Disease. J Lipid Res 54: 3227–3243.
266. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D et al. (2012). Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308: 788–795.
267. Ross MD, Malone E, Florida-James G (2015). Vascular Ageing and Exercise: Focus on Cellular Reparative Processes. Oxid Med Cell Longev 2016: 3583956.
268. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U et al. (2002). Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91: 837–844.
269. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G et al. (2008). Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 102: 923–932.
270. Sakharov DV, Muzykantov VR, Domogatsky SP, Danilov SM (1987). Protection of cultured endothelial cells from hydrogen peroxide-induced injury by antibody-conjugated catalase. Biochim Biophys Acta 930: 140–144.
271. Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH et al. (2003). Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 107: 947–953.
272. Santi D, Giannetta E, Isidori AM, Vitale C, Aversa A, Simoni M (2015). Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur J Endocrinol 172: R103–R114.
273. Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T et al. (2013). Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 61: 1736–1743.
274. Schachinger V, Britten MB, Zeiher AM (2000). Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899–1906.
275. Schleithoff C, Voelter-Mahlknecht S, Dahmke IN, Mahlknecht U (2012). On the epigenetics of vascular regulation and disease. Clin Epigenetics 4: 7.
276. Schmidt F, Kolle K, Kreuder K, Schnorbus B, Wild P, Hechtner M et al. (2015a). Nighttime aircraft noise impairs endothelial function and increases blood pressure in patients with or at high risk for coronary artery disease. Clin Res Cardiol 104: 23–30.
277. Schmidt FP, Basner M, Kroger G, Weck S, Schnorbus B, Muttray A et al. (2013). Effect of nighttime aircraft noise exposure on endothelial function and stress hormone release in healthy adults. Eur Heart J 34: 3508–3514a.
278. Schmidt HH, Stocker R, Vollbracht C, Paulsen G, Riley DP, Daiber A et al. (2015b). Antioxidants in Translational Medicine. Antioxid Redox Signal 23: 1130–1143.
279. Schnabel RB, Schulz A, Wild PS, Sinning CR, Wilde S, Eleftheriadis M et al. (2011). Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. Circ Cardiovasc Imaging 4: 371–380.
280. Schnabel RB, Wild PS, Schulz A, Zeller T, Sinning CR, Wilde S et al. (2012). Multiple endothelial biomarkers and noninvasive vascular function in the general population: the Gutenberg Health Study. Hypertension 60: 288–295.
281. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J et al. (2014). MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 20: 368–376.
282. Schulz E, Wenzel P, Munzel T, Daiber A (2014). Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal 20: 308–324.
283. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M et al. (2002). Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105: 1170–1175.
284. Selivanova O, Heinrich UR, Brieger J, Feltens R, Mann W (2007). Fast alterations of vascular endothelial growth factor (VEGF) expression and that of its receptors (Flt-1, Flk-1 and Neuropilin) in the cochlea of guinea pigs after moderate noise exposure. Eur Arch Otorhinolaryngol 264: 121–128.
285. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J et al. (2008). Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 300: 2123–2133.
286. Sharina IG, Sobolevsky M, Papakyriakou A, Rukoyatkina N, Spyroulias GA, Gambaryan S et al. (2015). The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies. Br J Pharmacol 172: 2316–2329.
287. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA (2011). GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 6: e25269.
288. Shechter M, Shechter A, Koren-Morag N, Feinberg MS, Hiersch L (2014). Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol 113: 162–167.
289. Shuvaev VV, Tliba S, Nakada M, Albelda SM, Muzykantov VR (2007). Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J Pharmacol Exp Ther 323: 450–457.
290. Shuvaev VV, Tliba S, Pick J, Arguiri E, Christofidou-Solomidou M, Albelda SM et al. (2011a). Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release 149: 236–241.
291. Shuvaev VV, Han J, Yu KJ, Huang S, Hawkins BJ, Madesh M et al. (2011b). PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J 25: 348–357.
292. Shuvaev VV, Christofidou-Solomidou M, Bhora F, Laude K, Cai H, Dikalov S et al. (2009). Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther 331: 404–411.
293. Shuvaev VV, Han J, Tliba S, Arguiri E, Christofidou-Solomidou M, Ramirez SH et al. (2013). Anti-inflammatory effect of targeted delivery of SOD to endothelium: mechanism, synergism with NO donors and protective effects in vitro and in vivo. PLoS One 8: e77002.
294. Simone E, Ding BS, Muzykantov V (2009a). Targeted delivery of therapeutics to endothelium. Cell Tissue Res 335: 283–300.
295. Simone EA, Dziubla TD, Discher DE, Muzykantov VR (2009b). Filamentous Polymer Nanocarriers of Tunable Stiffness that Encapsulate the Therapeutic Enzyme Catalase. Biomacromolecules 10: 1324–1330.
296. Simone EA, Dziubla TD, Colon-Gonzalez F, Discher DE, Muzykantov VR (2007). Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 8: 3914–3921.
297. Simone EA, Dziubla TD, Arguiri E, Vardon V, Shuvaev VV, Christofidou-Solomidou M et al. (2009c). Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm Res 26: 250–260.
298. Sinoway LI, Musch TI, Minotti JR, Zelis R (1986). Enhanced maximal metabolic vasodilatation in the dominant forearms of tennis players. J Appl Physiol 61: 673–678.
299. Siuda D, Zechner U, El Hajj N, Prawitt D, Langer D, Xia N et al. (2012). Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells. Basic Res Cardiol 107: 283.
300. Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT (2000). Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol 36: 94–102.
301. Small EM, Olson EN (2011). Pervasive roles of microRNAs in cardiovascular biology. Nature 469: 336–342.
302. Sodergren A, Karp K, Boman K, Eriksson C, Lundstrom E, Smedby T et al. (2010). Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 12: R158.
303. Soltesz P, Kerekes G, Der H, Szucs G, Szanto S, Kiss E et al. (2011). Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 10: 416–425.
304. Solzbach U, Hornig B, Jeserich M, Just H (1997). Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 96: 1513–1519.
305. Sorensen M, Hvidberg M, Andersen ZJ, Nordsborg RB, Lillelund KG, Jakobsen J et al. (2011). Road traffic noise and stroke: a prospective cohort study. Eur Heart J 32: 737–744.
306. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
307. Spieker LE, Flammer AJ, Luscher TF (2006). The vascular endothelium in hypertension. Handb Exp Pharmacol (176 Pt 2): 249–283.
308. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C et al. (2002). High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105: 1399–1402.
309. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552–2561.
310. Steven S, Munzel T, Daiber A (2015). Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease. Int J Mol Sci 16: 18185–18223.
311. Suessenbacher A, Dorler J, Wunder J, Hohenwarter F, Alber HF, Pachinger O et al. (2013). Comparison of brachial artery wall thickness versus endothelial function to predict late cardiovascular events in patients undergoing elective coronary angiography. Am J Cardiol 111: 671–675.
312. Sun X, He S, Wara AK, Icli B, Shvartz E, Tesmenitsky Y et al. (2014). Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 114: 32–40.
313. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A (2000). Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948–954.
314. Sweitzer TD, Thomas AP, Wiewrodt R, Nakada MT, Branco F, Muzykantov VR (2003). PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic Biol Med 34: 1035–1046.
315. Sydow K, Munzel T (2003). ADMA and oxidative stress. Atheroscler Suppl 4: 41–51.
316. Szabo C (2009). Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol 156: 713–727.
317. Szabo G, Radovits T, Veres G, Krieger N, Loganathan S, Sandner P et al. (2009). Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg 36: 657–664.
318. Szabo G, Seres L, Soos P, Gorenflo M, Merkely B, Horkay F et al. (2011). Tetrahydrobiopterin improves cardiac and pulmonary function after cardiopulmonary bypass. Eur J Cardiothorac Surg 40: 695–700.
319. Takase B, Etsuda H, Matsushima Y, Ayaori M, Kusano H, Hamabe A et al. (2004). Effect of chronic oral supplementation with vitamins on the endothelial function in chronic smokers. Angiology 55: 653–660.
320. Tanahashi K, Akazawa N, Miyaki A, Choi Y, Ra SG, Matsubara T et al. (2014). Aerobic exercise training decreases plasma asymmetric dimethylarginine concentrations with increase in arterial compliance in postmenopausal women. Am J Hypertens 27: 415–421.
321. Tarbell JM, Cancel LM (2016). The glycocalyx and its significance in human medicine. J Intern Med. doi: 10.1111/joim.12465.
322. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A (2003). Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107: 2805–2809.
323. Teede HJ, Giannopoulos D, Dalais FS, Hodgson J, McGrath BP (2006). Randomised, controlled, cross-over trial of soy protein with isoflavones on blood pressure and arterial function in hypertensive subjects. J Am Coll Nutr 25: 533–540.
324. Thorin E, Clozel M (2010). The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol 60: 1–26.
325. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kubler W (2000). Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 102: 2172–2179.
326. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC (2013). Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 19: 6064–6093.
327. Tousoulis D, Xenakis C, Tentolouris C, Davies G, Antoniades C, Crake T et al. (2005). Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina. Heart 91: 1319–1323.
328. Tsutsui JM, Xie F, Porter RT (2004). The use of microbubbles to target drug delivery. Cardiovasc Ultrasound 2: 23.
329. Uchida S, Dimmeler S (2015). Long noncoding RNAs in cardiovascular diseases. Circ Res 116: 737–750.
330. van Bussel BC, Henry RM, Ferreira I, van Greevenbroek MM, van der Kallen CJ, Twisk JW et al. (2015). A healthy diet is associated with less endothelial dysfunction and less low-grade inflammation over a 7-year period in adults at risk of cardiovascular disease. J Nutr 145: 532–540.
331. van den Berg BM, Nieuwdorp M, Stroes ES, Vink H (2006). Glycocalyx and endothelial (dys) function: from mice to men. Pharmacol Rep 58 (Suppl): 75–80.
332. van Rooij E, Olson EN (2012). MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11: 860–872.
333. Vasa-Nicotera M, Chen H, Tucci P, Yang AL, Saintigny G, Menghini R et al. (2011). miR-146a is modulated in human endothelial cell with aging. Atherosclerosis 217: 326–330.
334. Velmurugan S, Gan JM, Rathod KS, Khambata RS, Ghosh SM, Hartley A et al. (2016). Dietary nitrate improves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 103: 25–38.
335. Vena GA, Vestita M, Cassano N (2010). Psoriasis and cardiovascular disease. Dermatol Ther 23: 144–151.
336. Verma S, Wang CH, Lonn E, Charbonneau F, Buithieu J, Title LM et al. (2004). Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. Eur Heart J 25: 1754–1760.
337. Vienneau D, Schindler C, Perez L, Probst-Hensch N, Roosli M (2015). The relationship between transportation noise exposure and ischemic heart disease: a meta-analysis. Environ Res 138: 372–380.
338. Villanueva FS, Klibanov A, Wagner WR (2002). Microbubble-endothelial cell interactions as a basis for assessing endothelial function. Echocardiography 19: 427–438.
339. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC et al. (1990). Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81: 491–497.
340. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI (2013). Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 6: 99–109.
341. Vogel RA, Corretti MC, Plotnick GD (1997). Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 79: 350–354.
342. Waller K, Kaprio J, Lehtovirta M, Silventoinen K, Koskenvuo M, Kujala UM (2010). Leisure-time physical activity and type 2 diabetes during a 28 year follow-up in twins. Diabetologia 53: 2531–2537.
343. Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J et al. (2012). Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 221: 536–543.
344. Warnholtz A, Munzel T (2000). Why do antioxidants fail to provide clinical benefit? Curr Control Trials Cardiovasc Med 1: 38–40.
345. Warnholtz A, Mollnau H, Heitzer T, Kontush A, Moller-Bertram T, Lavall D et al. (2002). Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol 40: 1356–1363.
346. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001). Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685–E694.
347. Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A (2013). MicroRNA-126, −145, and −155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol 33: 449–454.
348. Wentland AL, Grist TM, Wieben O (2014). Review of MRI-based measurements of pulse wave velocity: a biomarker of arterial stiffness. Cardiovasc Diagn Ther 4: 193–206.
349. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S et al. (2011). Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 124: 1370–1381.
350. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al. (2005). Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999–1007.
351. Wethal T, Nedregaard B, Andersen R, Fossa A, Lund MB, Gunther A et al. (2014). Atherosclerotic lesions in lymphoma survivors treated with radiotherapy. Radiother Oncol 110: 448–454.
352. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM (1989). Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 80: 198–205.
353. Wilson SH, Celermajer DS, Nakagomi A, Wyndham RN, Janu MR, Ben Freedman S (1999). Vascular risk factors correlate to the extent as well as the severity of coronary atherosclerosis. Coron Artery Dis 10: 449–453.
354. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hubschle T et al. (2008). Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 325: 370–379.
355. Wojcik T, Szczesny E, Chlopicki S (2015). Detrimental effects of chemotherapeutics and other drugs on the endothelium: A call for endothelial toxicity profiling. Pharmacol Rep 67: 811–817.
356. Xia N, Forstermann U, Li H (2014). Resveratrol and endothelial nitric oxide. Molecules 19: 16102–16121.
357. Xia N, Daiber A, Forstermann U, Li H (2017). Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol 174: 1633–1646.
358. Xu S, Bai P, Little PJ, Liu P (2014). Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. Med Res Rev 34: 644–675.
359. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K et al. (2008). H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 322: 587–590.
360. Ying Z, Xie X, Bai Y, Chen M, Wang X, Zhang X et al. (2015). Exposure to concentrated ambient particulate matter induces reversible increase of heart weight in spontaneously hypertensive rats. Part Fibre Toxicol 12: 15.
361. Young JM, Shand BI, McGregor PM, Scott RS, Frampton CM (2006). Comparative effects of enzogenol and vitamin C supplementation versus vitamin C alone on endothelial function and biochemical markers of oxidative stress and inflammation in chronic smokers. Free Radic Res 40: 85–94.
362. Yuan S, Patel RP, Kevil CG (2015). Working with nitric oxide and hydrogen sulfide in biological systems. Am J Physiol Lung Cell Mol Physiol 308: L403–L415.
363. Zamora-Ros R, Serafini M, Estruch R, Lamuela-Raventos RM, Martinez-Gonzalez MA, Salas-Salvado J et al. (2013). Mediterranean diet and non enzymatic antioxidant capacity in the PREDIMED study: evidence for a mechanism of antioxidant tuning. Nutr Metab Cardiovasc Dis 23: 1167–1174.
364. Zampetaki A, Mayr M (2012). MicroRNAs in vascular and metabolic disease. Circ Res 110: 508–522.
365. Zampetaki A, Dudek K, Mayr M (2013). Oxidative stress in atherosclerosis: the role of microRNAs in arterial remodeling. Free Radic Biol Med 64: 69–77.
366. Zelcer S, Chen B, Mangel J, Vujovic O, Thiessen-Philbrook HR, Reider M et al. (2010). Impaired vascular function in asymptomatic young adult survivors of Hodgkin Lymphoma following mediastinal radiation. J Cancer Surviv 4: 218–224.
367. Zhang L, Zhou M, Qin G, Weintraub NL, Tang Y (2014). MiR-92a regulates viability and angiogenesis of endothelial cells under oxidative stress. Biochem Biophys Res Commun 446: 952–958.
368. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G et al. (2008). Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 80: 191–199.
369. Zhang Y, Qiu J, Wang X, Zhang Y, Xia M (2011). AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler Thromb Vasc Biol 31: 2897–2908.